M 9831

Drug Profile

M 9831

Alternative Names: M9831; VX 984

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck KGaA
  • Class Antineoplastics
  • Mechanism of Action DNA activated protein kinase inhibitors; DNA repair enzyme modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Oct 2017 Vertex Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (PO) (NCT02644278)
  • 11 Jan 2017 VX 984 licensed to Merck KGaA worldwide
  • 11 Oct 2016 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top